Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age
- 1 January 2008
- journal article
- research article
- Published by Informa UK Limited in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 21 (1), 41-52
- https://doi.org/10.1080/14767050701831397
Abstract
Objectives. Preeclampsia is considered an anti-angiogenic state. A role for the anti-angiogenic factors soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and soluble endoglin in preeclampsia has been proposed. Soluble vascular endothelial growth factor receptor-2 (sVEGFR-2) has been detected in human plasma, and the recombinant form of this protein has anti-angiogenic activity. There is a paucity of information about maternal plasma sVEGFR-2 concentrations in patients with preeclampsia and those without preeclampsia with small for gestational age (SGA) fetuses. This study was conducted to determine whether: (1) plasma sVEGFR-2 concentration changes throughout pregnancy; and (2) preeclampsia and SGA are associated with abnormalities in the maternal plasma concentration of sVEGFR-2. Study design. This cross-sectional study included non-pregnant women (n = 40), women with normal pregnancies (n = 135), women with an SGA fetus (n = 53), and women with preeclampsia (n = 112). SGA was defined as an ultrasound-estimated fetal weight below the 10th percentile for gestational age that was confirmed by neonatal birth weight. Plasma concentrations of sVEGFR-2 were determined by ELISA. Results. (1) There was no significant difference in the mean plasma concentration of sVEGFR-2 between non-pregnant women and those with normal pregnancies (p = 0.8); (2) patients with preeclampsia and those without preeclampsia with SGA fetuses had a lower mean plasma concentration of sVEGFR-2 than that of women with normal pregnancies (p < 0.001 for both); and (3) there was no significant difference in the mean plasma concentration of sVEGFR-2 between patients with preeclampsia and those without preeclampsia with SGA (p = 0.9). Conclusions. Preeclampsia and SGA are associated with low plasma concentrations of sVEGFR-2. One interpretation of the findings is that plasma sVEGFR-2 concentration could reflect endothelial cell function.Keywords
This publication has 127 references indexed in Scilit:
- Oxidative stress in midpregnancy as a predictor of gestational hypertension and pre‐eclampsiaBJOG: An International Journal of Obstetrics and Gynaecology, 2006
- Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritisAmerican Journal of Obstetrics and Gynecology, 2006
- Altered Metabolic Profiles among Older Mothers with a History of PreeclampsiaGynecologic and Obstetric Investigation, 2005
- Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia developAmerican Journal of Obstetrics and Gynecology, 2004
- Insulin Resistance and Alterations in AngiogenesisHypertension, 2004
- Circulating Angiogenic Factors and the Risk of PreeclampsiaNew England Journal of Medicine, 2004
- Angiogenic growth factors and hypertensionAngiogenesis, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996
- Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endotheliumNature, 1995